GP88 (progranulin)

A novel tissue and circulating biomarker for non-small cell lung carcinoma

Martin J. Edelman, Josephine Feliciano, Binbin Yue, Pablo Bejarano, Olga Ioffe, David Reisman, Douglas Hawkins, Qiwei Gai, David Hicks, Ginette Serrero

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Summary GP88 (progranulin) is a growth and survival factor implicated in tumorigenesis and drug resistance. Previous studies showed that GP88 was expressed in breast cancer tissue in inverse correlation with survival. This study evaluates GP88 tissue expression in localized/locally advanced lung cancer and GP88 serum levels in advanced disease. GP88 expression was determined by immunohistochemistry in tumor tissue from non-small cell lung carcinoma (NSCLC) patients, 85 with localized (stage I-II), and 40 with locally advanced disease (stage IIIa) and correlated with clinical outcome. Serum GP88 levels from stage IIIb/IV patients, quantified by enzyme immunoassay were compared with GP88 levels from patients with chronic obstructive pulmonary disease and healthy individuals. GP88 was expressed in more than 80% adenocarcinoma and squamous cell carcinoma in contrast to normal lung or small cell lung cancer. There was a statistically significant inverse association of GP88 expression (GP88 immunohistochemistry score, 3+ versus < 3+) with survival for patients with localized resected NSCLC with hazard ratio (HR) = 2.28 (P =.0076) for disease-free survival and HR = 2.17 (P =.014) for overall survival. A statistically significant decrease in progression-free survival (HR = 2.9; P =.022) for GP88 scores of 3+ versus less than 3+ was observed for stage IIIa after chemoradiotherapy. In addition, serum GP88 was significantly elevated in stage IIIb/IV NSCLC compared with control subjects (49.9 ng/mL versus 28.4 ng/mL; P <.0001). This is the first study demonstrating GP88 tissue and serum expression as a prognostic biomarker in localized and advanced disease. Future research will determine utility of monitoring GP88 and the potential of GP88 expression as a predictive marker for anti-GP88 therapeutics.

Original languageEnglish
Pages (from-to)1893-1899
Number of pages7
JournalHuman Pathology
Volume45
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Survival
Serum
Disease-Free Survival
Immunohistochemistry
Small Cell Lung Carcinoma
Chemoradiotherapy
Immunoenzyme Techniques
Drug Resistance
Chronic Obstructive Pulmonary Disease
Squamous Cell Carcinoma
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Adenocarcinoma
Breast Neoplasms
Lung
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Edelman, M. J., Feliciano, J., Yue, B., Bejarano, P., Ioffe, O., Reisman, D., ... Serrero, G. (2014). GP88 (progranulin): A novel tissue and circulating biomarker for non-small cell lung carcinoma. Human Pathology, 45(9), 1893-1899. https://doi.org/10.1016/j.humpath.2014.05.011

GP88 (progranulin) : A novel tissue and circulating biomarker for non-small cell lung carcinoma. / Edelman, Martin J.; Feliciano, Josephine; Yue, Binbin; Bejarano, Pablo; Ioffe, Olga; Reisman, David; Hawkins, Douglas; Gai, Qiwei; Hicks, David; Serrero, Ginette.

In: Human Pathology, Vol. 45, No. 9, 01.01.2014, p. 1893-1899.

Research output: Contribution to journalArticle

Edelman, MJ, Feliciano, J, Yue, B, Bejarano, P, Ioffe, O, Reisman, D, Hawkins, D, Gai, Q, Hicks, D & Serrero, G 2014, 'GP88 (progranulin): A novel tissue and circulating biomarker for non-small cell lung carcinoma', Human Pathology, vol. 45, no. 9, pp. 1893-1899. https://doi.org/10.1016/j.humpath.2014.05.011
Edelman, Martin J. ; Feliciano, Josephine ; Yue, Binbin ; Bejarano, Pablo ; Ioffe, Olga ; Reisman, David ; Hawkins, Douglas ; Gai, Qiwei ; Hicks, David ; Serrero, Ginette. / GP88 (progranulin) : A novel tissue and circulating biomarker for non-small cell lung carcinoma. In: Human Pathology. 2014 ; Vol. 45, No. 9. pp. 1893-1899.
@article{89d1bafe1253498c8c350aeb5cd77a92,
title = "GP88 (progranulin): A novel tissue and circulating biomarker for non-small cell lung carcinoma",
abstract = "Summary GP88 (progranulin) is a growth and survival factor implicated in tumorigenesis and drug resistance. Previous studies showed that GP88 was expressed in breast cancer tissue in inverse correlation with survival. This study evaluates GP88 tissue expression in localized/locally advanced lung cancer and GP88 serum levels in advanced disease. GP88 expression was determined by immunohistochemistry in tumor tissue from non-small cell lung carcinoma (NSCLC) patients, 85 with localized (stage I-II), and 40 with locally advanced disease (stage IIIa) and correlated with clinical outcome. Serum GP88 levels from stage IIIb/IV patients, quantified by enzyme immunoassay were compared with GP88 levels from patients with chronic obstructive pulmonary disease and healthy individuals. GP88 was expressed in more than 80{\%} adenocarcinoma and squamous cell carcinoma in contrast to normal lung or small cell lung cancer. There was a statistically significant inverse association of GP88 expression (GP88 immunohistochemistry score, 3+ versus < 3+) with survival for patients with localized resected NSCLC with hazard ratio (HR) = 2.28 (P =.0076) for disease-free survival and HR = 2.17 (P =.014) for overall survival. A statistically significant decrease in progression-free survival (HR = 2.9; P =.022) for GP88 scores of 3+ versus less than 3+ was observed for stage IIIa after chemoradiotherapy. In addition, serum GP88 was significantly elevated in stage IIIb/IV NSCLC compared with control subjects (49.9 ng/mL versus 28.4 ng/mL; P <.0001). This is the first study demonstrating GP88 tissue and serum expression as a prognostic biomarker in localized and advanced disease. Future research will determine utility of monitoring GP88 and the potential of GP88 expression as a predictive marker for anti-GP88 therapeutics.",
author = "Edelman, {Martin J.} and Josephine Feliciano and Binbin Yue and Pablo Bejarano and Olga Ioffe and David Reisman and Douglas Hawkins and Qiwei Gai and David Hicks and Ginette Serrero",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.humpath.2014.05.011",
language = "English",
volume = "45",
pages = "1893--1899",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - GP88 (progranulin)

T2 - A novel tissue and circulating biomarker for non-small cell lung carcinoma

AU - Edelman, Martin J.

AU - Feliciano, Josephine

AU - Yue, Binbin

AU - Bejarano, Pablo

AU - Ioffe, Olga

AU - Reisman, David

AU - Hawkins, Douglas

AU - Gai, Qiwei

AU - Hicks, David

AU - Serrero, Ginette

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Summary GP88 (progranulin) is a growth and survival factor implicated in tumorigenesis and drug resistance. Previous studies showed that GP88 was expressed in breast cancer tissue in inverse correlation with survival. This study evaluates GP88 tissue expression in localized/locally advanced lung cancer and GP88 serum levels in advanced disease. GP88 expression was determined by immunohistochemistry in tumor tissue from non-small cell lung carcinoma (NSCLC) patients, 85 with localized (stage I-II), and 40 with locally advanced disease (stage IIIa) and correlated with clinical outcome. Serum GP88 levels from stage IIIb/IV patients, quantified by enzyme immunoassay were compared with GP88 levels from patients with chronic obstructive pulmonary disease and healthy individuals. GP88 was expressed in more than 80% adenocarcinoma and squamous cell carcinoma in contrast to normal lung or small cell lung cancer. There was a statistically significant inverse association of GP88 expression (GP88 immunohistochemistry score, 3+ versus < 3+) with survival for patients with localized resected NSCLC with hazard ratio (HR) = 2.28 (P =.0076) for disease-free survival and HR = 2.17 (P =.014) for overall survival. A statistically significant decrease in progression-free survival (HR = 2.9; P =.022) for GP88 scores of 3+ versus less than 3+ was observed for stage IIIa after chemoradiotherapy. In addition, serum GP88 was significantly elevated in stage IIIb/IV NSCLC compared with control subjects (49.9 ng/mL versus 28.4 ng/mL; P <.0001). This is the first study demonstrating GP88 tissue and serum expression as a prognostic biomarker in localized and advanced disease. Future research will determine utility of monitoring GP88 and the potential of GP88 expression as a predictive marker for anti-GP88 therapeutics.

AB - Summary GP88 (progranulin) is a growth and survival factor implicated in tumorigenesis and drug resistance. Previous studies showed that GP88 was expressed in breast cancer tissue in inverse correlation with survival. This study evaluates GP88 tissue expression in localized/locally advanced lung cancer and GP88 serum levels in advanced disease. GP88 expression was determined by immunohistochemistry in tumor tissue from non-small cell lung carcinoma (NSCLC) patients, 85 with localized (stage I-II), and 40 with locally advanced disease (stage IIIa) and correlated with clinical outcome. Serum GP88 levels from stage IIIb/IV patients, quantified by enzyme immunoassay were compared with GP88 levels from patients with chronic obstructive pulmonary disease and healthy individuals. GP88 was expressed in more than 80% adenocarcinoma and squamous cell carcinoma in contrast to normal lung or small cell lung cancer. There was a statistically significant inverse association of GP88 expression (GP88 immunohistochemistry score, 3+ versus < 3+) with survival for patients with localized resected NSCLC with hazard ratio (HR) = 2.28 (P =.0076) for disease-free survival and HR = 2.17 (P =.014) for overall survival. A statistically significant decrease in progression-free survival (HR = 2.9; P =.022) for GP88 scores of 3+ versus less than 3+ was observed for stage IIIa after chemoradiotherapy. In addition, serum GP88 was significantly elevated in stage IIIb/IV NSCLC compared with control subjects (49.9 ng/mL versus 28.4 ng/mL; P <.0001). This is the first study demonstrating GP88 tissue and serum expression as a prognostic biomarker in localized and advanced disease. Future research will determine utility of monitoring GP88 and the potential of GP88 expression as a predictive marker for anti-GP88 therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84908867330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908867330&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.05.011

DO - 10.1016/j.humpath.2014.05.011

M3 - Article

VL - 45

SP - 1893

EP - 1899

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 9

ER -